Pharmacological Treatment for Asymptomatic ASD with Left-to-Right Shunt

Primary Management Approach

The American College of Cardiology and American Heart Association recommend that asymptomatic adults with atrial septal defect and left-to-right shunt require no pharmacological therapy if the right ventricle is normal in size 1, 2
The American College of Cardiology and American Heart Association guidelines state that patients with small shunts and normal RV size are generally asymptomatic and require no medical therapy 1, 2

Asymptomatic patients without RV enlargement should be monitored clinically every 6-12 months for development of symptoms, particularly arrhythmias and paradoxical embolic events 1, 2
Repeat echocardiography every 2-3 years to assess RV size, function, and pulmonary artery pressure is recommended for asymptomatic patients without RV enlargement 1, 2, 3

The American College of Cardiology recommends cardioversion after appropriate anticoagulation to restore sinus rhythm if atrial fibrillation or flutter occurs (Class I) 2
Both antiarrhythmic therapy and anticoagulation should be used if atrial fibrillation develops, according to the American College of Cardiology 1, 2
Rate control and anticoagulation are required if sinus rhythm cannot be maintained, as recommended by the American College of Cardiology 2

Pharmacotherapy for PAH is only indicated for patients with irreversible PAH who are not eligible for ASD closure, and may include endothelin-receptor antagonists and PDE-5 inhibitors, as suggested by the American College of Cardiology 4, 5, 6

The presence of RV enlargement is the trigger for intervention, not medication, and closure (percutaneous or surgical) is indicated when RV volume overload develops, as recommended by the American College of Cardiology (Class I) 4, 5, 7

The American Heart Association and American College of Cardiology explicitly note that heart failure medications should not be prescribed prophylactically for uncomplicated ASD, due to lack of data 4, 5, 6
ACE inhibitors, ARBs, or beta-blockers should not be used routinely for ASD without specific indications (hypertension, coronary disease, systolic dysfunction), as small studies in ACHD populations show no significant benefit on ventricular function or exercise capacity, according to the American College of Cardiology 4, 5, 6

Reduced LV compliance from hypertension, coronary artery disease, or acquired valvular disease increases left-to-right shunting across an existing ASD, and treating the underlying condition with standard therapies is recommended, as suggested by the American College of Cardiology 1, 2, 6
Reassessing for closure indications is necessary, as the increased shunt may now cause RV enlargement, according to the American College of Cardiology 1, 2, 8